Prex is a ChK1/2 inhibitor currently in several phase 2 clinical trials, both as single agent and in combination with chemotherapy, in ovarian cancer [16]; breast cancer and colon cancer [17]; and in a phase 1 trial for pediatric patients with recurrent or refractory brain tumors [18]. Here, CHEK1 is linked to breast carcinoma.